Spevigo
What Spevigo is used for
Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. Spevigo is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Conditional approval: approved on less complete data because the need is high; more data must follow.
Key facts
- Brand
- Spevigo
- Active substance
- spesolimab
- Disease area
- Psoriasis
- Medicine group
- Immunosuppressants
- ATC code
- L04AC22
- Marketing authorisation holder
- LEO Pharma A/S
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Spevigo
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Spevigo used for?
Spevigo is indicated for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age. Spevigo is indicated for the treatment of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy.
What is the active substance in Spevigo?
Spevigo contains spesolimab.
Who makes Spevigo?
The EU marketing authorisation holder is LEO Pharma A/S.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU